Engimmune Therapeutics
PrivateLast Round
Seed
May 3, 2022
Total Funding Raised
$16.7M
Company Overview
Engimmune Therapeutics operates in Healthcare & Life Sciences and is based in Allschwil. Its latest recorded funding round was a Seed round in May 2022.
Engimmune Therapeutics is a biotechnology company that develops targeted, 'off-the-shelf' soluble T-cell receptor (TCR) drugs to treat solid tumour cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Engimmune Therapeutics Comparables
Compare Engimmune Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Stereo Biotherapeutics | 87% | |
| Etcembly | 85% | |
| 3T Biosciences | 83% |
For institutional investors. Book with your work email.
Engimmune Therapeutics Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Engimmune Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Novo Holdings | Seed |
| Pureos Bioventures | Seed |
| BaseLaunch | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 16, 2023
Grew 19% QoQ, from 21 to 25 employees.
- May 3, 2022
$17M round led by Novo Holdings and Pureos Bioventures.
For institutional investors. Book with your work email.
Engimmune Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Engimmune Therapeutics's valuation, stock price, and market status.
Is Engimmune Therapeutics a public or private company?
Engimmune Therapeutics is a private company.
What is the current stock price of Engimmune Therapeutics?
Engimmune Therapeutics is a private company, so its shares have no public market price. Caplight tracks Engimmune Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Engimmune Therapeutics worth (valuation)?
Valuation information for Engimmune Therapeutics is not publicly available.
Can I buy Engimmune Therapeutics stock?
Engimmune Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Engimmune Therapeutics's last funding round?
Engimmune Therapeutics's most recent funding round was Seed on May 3, 2022.
Who are the main investors in Engimmune Therapeutics?
Key investors in Engimmune Therapeutics include Novo Holdings, Pureos Bioventures.
Will Engimmune Therapeutics IPO soon?
No public IPO plans have been announced for Engimmune Therapeutics.
How can I track Engimmune Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Engimmune Therapeutics's shares on secondary markets.